ASTHMA
MCID: AST005
MIFTS: 75

Asthma (ASTHMA)

Categories: Genetic diseases, Immune diseases, Mental diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Asthma

MalaCards integrated aliases for Asthma:

Name: Asthma 57 12 73 20 72 72 36 29 54 6 42 3 44 15 37 62 62 17 70 32
Chronic Obstructive Asthma 12 54 17 70
Asthma, Susceptibility to 57 29 6 39
Asthma, Diminished Response to Antileukotriene Treatment in 57 13 6
Bronchial Hyperreactivity 12 54 70
Asthma, Nocturnal, Susceptibility to 57 6
Asthma, Protection Against 57 6
Chronic Obstructive Asthma with Acute Exacerbation 12
Chronic Obstructive Asthma with Status Asthmaticus 12
Asthma-Related Traits, Susceptibility to 57
Asthma, Exercise-Induced 70
Exercise-Induced Asthma 12
Exercise Induced Asthma 12
Asthma-Related Traits 57
Asthma, Bronchial 57
Asthma, Nocturnal 57
Nocturnal Asthma 12
Bronchial Asthma 72

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant vs. multifactorial



Classifications:



External Ids:

Disease Ontology 12 DOID:0080826 DOID:2841
OMIM® 57 600807
KEGG 36 H00079
ICD9CM 34 493
MeSH 44 D001249
NCIt 50 C28397
SNOMED-CT 67 187687003
ICD10 32 J45 J45.9
SNOMED-CT via HPO 68 195967001 263681008 991000119106
UMLS 70 C0004096 C0004099 C0085129 more

Summaries for Asthma

MedlinePlus : 42 Asthma is a chronic disease that affects your airways. Your airways are tubes that carry air in and out of your lungs. If you have asthma, the inside walls of your airways become sore and swollen. That makes them very sensitive, and they may react strongly to things that you are allergic to or find irritating. When your airways react, they get narrower and your lungs get less air. Symptoms of asthma include Wheezing Coughing, especially early in the morning or at night Chest tightness Shortness of breath Not all people who have asthma have these symptoms. Having these symptoms doesn't always mean that you have asthma. Your doctor will diagnose asthma based on lung function tests, your medical history, and a physical exam. You may also have allergy tests. When your asthma symptoms become worse than usual, it's called an asthma attack. Severe asthma attacks may require emergency care, and they can be fatal. Asthma is treated with two kinds of medicines: quick-relief medicines to stop asthma symptoms and long-term control medicines to prevent symptoms. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Asthma, also known as chronic obstructive asthma, is related to allergic asthma and exercise-induced bronchoconstriction, and has symptoms including chest tightness, coughing and shortness of breath. An important gene associated with Asthma is IL13 (Interleukin 13), and among its related pathways/superpathways are Asthma and Allograft rejection. The drugs Guaifenesin and Phenylpropanolamine have been mentioned in the context of this disorder. Affiliated tissues include Lung, smooth muscle and t cells, and related phenotype is asthma.

Disease Ontology : 12 A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors. The disease has symptom recurring periods of wheezing (a whistling sound while breathing), has symptom chest tightness, has symptom shortness of breath, has symptom mucus production and has symptom coughing.

GARD : 20 Asthma is a breathing disorder that affects the airways. People with this condition experience recurrent swelling and narrowing of the airways of the lungs which is associated with wheezing, shortness of breath, chest tightness, and coughing. Most affected people have episodes of symptoms ("asthma attacks") followed by symptom-free periods; however, some may experience persistent shortness of breath in between attacks. Asthma is considered a complex or multifactorial condition that is likely due to a combination of multiple genetic, environmental, and lifestyle factors. Many people with asthma have a personal or family history of allergies, such as hay fever or eczema. Having a family member with asthma is associated with an increased risk of developing the condition. Treatment generally includes various medications, both to prevent asthma attacks and to provide quick relief during an attack.

OMIM® : 57 Bronchial asthma is the most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, and dyspnea; bronchial hyperresponsiveness (BHR) as assessed by methacholine challenge test; serum IgE levels; atopy; and atopic dermatitis (Laitinen et al., 2001; Illig and Wjst, 2002; Pillai et al., 2006). See 147050 for information on the asthma-associated phenotype atopy. (600807) (Updated 20-May-2021)

CDC : 3 Asthma is a disease that affects your lungs. It causes repeated episodes of wheezing, breathlessness, chest tightness, and nighttime or early morning coughing. Asthma can be controlled by taking medicine and avoiding the triggers that can cause an attack. You must also remove the triggers in your environment that can make your asthma worse.

KEGG : 36 Asthma is a complex syndrome with many clinical phenotypes in both adults and children. Its major characteristics include a variable degree of airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Inhaled allergens encounter antigen presenting cells (APC) that line the airway. Upon recognition of the antigen and activation by APC, naive T cells differentiate into TH2 cells. Activated TH2 stimulate the formation of IgE by B cells. IgE molecules bind to IgE receptors located on mast cells. The crosslinking of mast-cell-bound IgE by allergens leads to the release of biologically active mediators (histamine, leukotrienes) by means of degranulation and, so, to the immediate symptoms of allergy. Mast cells also release chemotactic factors that contribute to the recruitment of inflammatory cells, particularly eosinophils, whose proliferation and differentiation from bone marrow progenitors is promoted by IL-5. The activation of eosinophils leads to release of toxic granules and oxygen free radicals that lead to tissue damage and promote the development of chronic inflammation.

Novus Biologicals : 55 Asthma is a chronic lung disease that causes inflammation, thickening and narrowing of airways, as well as an overproduction of mucus. More than 300 million people worldwide suffer from asthma. Asthma symptoms include wheezing, shortness of breath, coughing and tightness of the chest. Interleukin 13 (IL-13) is the key effector cytokine in asthma. IL-13 stimulates airway fibrosis via action of matrix metalloproteinases (MMPs) on tumor transforming growth factor beta (TGN-beta), and also promotes epithelial damage, mucus production and an increased concentration of eosinophils. The inflammatory response characteristic of asthma is augmented by the production of IL-13 and other TH2 cytokines.

UniProtKB/Swiss-Prot : 72 Asthma: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.

PubMed Health : 62 About asthma: Asthma (AZ-ma) is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The coughing often occurs at night or early in the morning. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma. About 7 million of these people are children.

Wikipedia : 73 Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable... more...

Related Diseases for Asthma

Diseases in the Asthma family:

Chronic Asthma Acute Asthma
Adult-Onset Severe Asthma

Diseases related to Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1413)
# Related Disease Score Top Affiliating Genes
1 allergic asthma 34.1 RNASE3 NPSR1 IL13 CCL11 ALOX5
2 exercise-induced bronchoconstriction 33.5 RNASE3 IL13 CYSLTR1 ALOX5
3 acute asthma 33.5 RNASE3 ALOX5 ADRB2
4 chronic asthma 33.4 RNASE3 IL13 CCL11 ALOX5
5 allergic rhinitis 33.4 RNASE3 IL13 CCL11 ALOX5
6 status asthmaticus 33.3 RNASE3 CCL11 ADRB2
7 ige responsiveness, atopic 33.3 RNASE3 PLA2G7 IL13
8 rhinitis 33.3 TNF RNASE3 IL13 CYSLTR1 CCL11
9 dermatitis, atopic 33.3 TNF RNASE3 IL13 CYSLTR1 CCL11
10 dermatitis 33.2 TNF RNASE3 NPSR1 IL13 CCL11
11 childhood-onset asthma 33.1 RNASE3 IL13
12 intrinsic asthma 33.0 RNASE3 IL13
13 churg-strauss syndrome 33.0 TNF RNASE3 CYSLTR1 CCL11
14 hypereosinophilic syndrome 32.9 RNASE3 IL13 CCL11 ALOX5
15 near-fatal asthma 32.9 TNF ADRB2
16 bronchitis 32.9 TNF RNASE3 IL13 CCL11
17 pollen allergy 32.9 RNASE3 IL13 ADRB2
18 allergic disease 32.9 TNF RNASE3 IL13 CCL11 ADRB2
19 lung disease 32.8 TNF RNASE3 IL13 ADRB2
20 pulmonary disease, chronic obstructive 32.7 TNF RNASE3 MIR126 IL13 CCL11 ADRB2
21 proteasome-associated autoinflammatory syndrome 1 32.6 TNF RNASE3 IL13 CCL11 ALOX5
22 urticaria 32.5 TNF RNASE3 IL13 HNMT CYSLTR1 ALOX5
23 esophagitis, eosinophilic, 1 32.4 RNASE3 IL13 CCL11
24 bronchiolitis 32.4 TNF RNASE3 IL13 CCL11
25 latex allergy 32.4 TNF RNASE3 IL13
26 food allergy 32.3 TNF RNASE3 IL13
27 conjunctivitis 32.2 TNF RNASE3 IL13 CCL11
28 respiratory failure 32.2 TNF RNASE3 MIR126 IL13 CCL11 ALOX5
29 common cold 32.1 TNF RNASE3 IL13 CYSLTR1 CCL11
30 eosinophilic pneumonia 31.9 RNASE3 IL13 CCL11
31 pulmonary eosinophilia 31.9 RNASE3 IL13 CYSLTR1 CCL11
32 body mass index quantitative trait locus 11 31.9 TNF PLA2G7 MIR126 CCL11 BRCA2 ALOX5
33 esophagitis 31.8 TNF RNASE3 IL13 CCL11
34 allergic conjunctivitis 31.8 TNF RNASE3 IL13 CCL11
35 otitis media 31.7 TNF RNASE3 CCL11
36 chronic urticaria 31.7 TNF RNASE3 IL13 HNMT CYSLTR1
37 inflammatory bowel disease 31.6 TNF NPSR1 IL13 HLA-G CCL11 ALOX5
38 bronchial disease 31.6 TNF RNASE3 MIR126 IL13 CYSLTR1 CCL11
39 adult respiratory distress syndrome 31.4 TNF PLA2G7 ALOX5 ADRB2
40 gastroenteritis 31.4 TNF RNASE3 CCL11
41 immune system disease 31.4 TNF MIR148A MIR126 IL13
42 milk allergy 31.4 TNF RNASE3 IL13
43 schistosomiasis 31.2 TNF RNASE3 IL13
44 toxocariasis 31.2 RNASE3 IL13
45 skin disease 31.2 TNF RNASE3 MIR126 IL13 CCL11
46 paranasal sinus disease 31.1 TNF RNASE3 IL13 CCL11 ALOX5
47 parasitic helminthiasis infectious disease 31.1 TNF RNASE3 IL13 CCL11
48 myocardial infarction 31.1 TNF PLA2G7 MIR126 CCL11 ALOX5 ADRB2
49 vasomotor rhinitis 31.1 RNASE3 IL13
50 keratoconjunctivitis 31.1 TNF RNASE3 IL13 CCL11

Comorbidity relations with Asthma via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Osteoporosis
Respiratory Failure Status Asthmaticus

Graphical network of the top 20 diseases related to Asthma:



Diseases related to Asthma

Symptoms & Phenotypes for Asthma

Human phenotypes related to Asthma:

31
# Description HPO Frequency HPO Source Accession
1 asthma 31 HP:0002099

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Resp:
asthma
airway hyperresponsiveness

Clinical features from OMIM®:

600807 (Updated 20-May-2021)

Symptoms:

12
  • chest tightness
  • coughing
  • shortness of breath
  • recurring periods of wheezing
  • mucus production

UMLS symptoms related to Asthma:


dyspnea; cyanosis; wheezing; snoring; coughing; labored breathing; sneezing; spasm; expiratory wheeze

Drugs & Therapeutics for Asthma

PubMed Health treatment related to Asthma: 62

Asthma is a long-term disease that has no cure. The goal of asthma treatment is to control the disease. Good asthma control will: Prevent chronic and troublesome symptoms, such as coughing and shortness of breath Reduce your need for quick-relief medicines (see below) Help you maintain good lung function Let you maintain your normal activity level and sleep through the night Prevent asthma attacks that could result in an emergency room visit or hospital stay To control asthma , partner with your doctor to manage your asthma or your child's asthma. Children aged 10 or older—and younger children who are able—should take an active role in their asthma care. Taking an active role to control your asthma involves: Working with your doctor to treat other conditions that can interfere with asthma management. Avoiding things that worsen your asthma (asthma triggers). However, one trigger you should not avoid is physical activity. Physical activity is an important part of a healthy lifestyle. Talk with your doctor about medicines that can help you stay active. Working with your doctor and other health care providers to create and follow an asthma action plan. An asthma action plan gives guidance on taking your medicines properly, avoiding asthma triggers (except physical activity), tracking your level of asthma control, responding to worsening symptoms, and seeking emergency care when needed. Asthma is treated with two types of medicines: long-term control and quick-relief medicines. Long-term control medicines help reduce airway inflammation and prevent asthma symptoms . Quick-relief, or "rescue," medicines relieve asthma symptoms that may flare up. Your initial treatment will depend on the severity of your asthma . Followup asthma treatment will depend on how well your asthma action plan is controlling your symptoms and preventing asthma attacks. Your level of asthma control can vary over time and with changes in your home, school, or work environments. These changes can alter how often you're exposed to the factors that can worsen your asthma. Your doctor may need to increase your medicine if your asthma doesn't stay under control. On the other hand , if your asthma is well controlled for several months, your doctor may decrease your medicine. These adjustments to your medicine will help you maintain the best control possible with the least amount of medicine necessary. Asthma treatment for certain groups of people—such as children, pregnant women, or those for whom exercise brings on asthma symptoms —will be adjusted to meet their special needs.

Drugs for Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 507)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Cisatracurium Approved Phase 4 96946-41-7 62887
7
Etomidate Approved Phase 4 33125-97-2 36339 667484
8
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Montelukast Approved Phase 4 158966-92-8 5281040
11
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
12
Adenosine Approved, Investigational Phase 4 58-61-7 60961
13
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
14
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
15
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
16
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
17
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
18
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
19
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
20
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
21
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
22
Oxcarbazepine Approved Phase 4 28721-07-5 34312
23
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
24
Cetirizine Approved Phase 4 83881-51-0 2678
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Clarithromycin Approved Phase 4 81103-11-9 84029
27
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
28
Lithium carbonate Approved Phase 4 554-13-2
29
Citalopram Approved Phase 4 59729-33-8 2771
30
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
31
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
32
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
33
Sertraline Approved Phase 4 79617-96-2 68617
34
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
35
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
36
Propranolol Approved, Investigational Phase 4 525-66-6 4946
37
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
38
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
39
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
40
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
41
Promethazine Approved, Investigational Phase 4 60-87-7 4927
42
Benralizumab Approved, Investigational Phase 4 1044511-01-4
43
Terbutaline Approved Phase 4 23031-25-6 5403
44
Theophylline Approved Phase 4 58-55-9 2153
45
Lactitol Approved, Investigational Phase 4 585-86-4 157355
46
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
47
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
48
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
49
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
50
Metronidazole Approved Phase 4 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 3647)
# Name Status NCT ID Phase Drugs
1 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
2 Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
3 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
4 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
5 Assessing Decision Maker Tools for Asthma: the Asthma APGAR Unknown status NCT01446315 Phase 4
6 Inflammatory, Functional and Image Composite Measure to Define Asthma Control Unknown status NCT00597064 Phase 4 prednisone
7 Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
8 A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
9 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
10 Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Unknown status NCT02934945 Phase 4 budesonide 160μg/formoterol 4.5μg
11 Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial Unknown status NCT00900874 Phase 4 salbutamol;Formoterol
12 The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial. Unknown status NCT03021161 Phase 4 Probiotic Formula
13 A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children Unknown status NCT00624429 Phase 4 Budesonide respules
14 Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration. Unknown status NCT00914797 Phase 4 inhaled and oral terbutaline
15 A Multicentered, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Procaterol Hydrochloride With Inhaled Glucocorticoid in Treatment Patients With Cough Variant Asthma (CVA) Unknown status NCT01170429 Phase 4 Procaterol hydrochloride;Meptin placebo
16 Asthma and Vitamin D (a Clinical Pilot Study) Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
17 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Unknown status NCT03652376 Phase 4 Benralizumab
18 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Unknown status NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
19 Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial Unknown status NCT02584738 Phase 4 Nebulized Magnesium Sulfate;Nebulized isotonic saline;Nebulized Salbutamol;Ipratropium bromide;Methylprednisolone or Prednisolone
20 Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Leukotriene Modulator Montelukast Alone or Combined With Inhaled Corticosteroid on Cough Variant Asthma Unknown status NCT01404013 Phase 4 ICS/LABA;Montelukast;ICS/LABA and Montelukast
21 Inhaler Technique Education in Elderly Patients With Asthma or COPD: Impact on Disease Exacerbations - a Protocol for a Single-blinded Randomised Controlled Trial Unknown status NCT03449316 Phase 4
22 Randomised, Double-blinded, Placebo-Controlled Study of Therapeutic Effect of Su-Huang Antitussive Capsule on Cough Variant Asthma(CVA) Unknown status NCT01584804 Phase 4 Su-Huang antitussive capsule;Sugar pill
23 Does a Low Exhaled Nitric Oxide Level Exclude a Clinical Benefit From Inhaled Corticosteroids in Suspected Asthma: A Randomised, Placebo Controlled Trial Unknown status NCT02771717 Phase 4 Budesonide (Pulmicort);Placebo - dummy inhaler
24 Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma Unknown status NCT00914654 Phase 4 inhaled formoterol
25 Blood and Urinary Concentrations of Inhaled Salmeterol in Asthmatic Subjects and Elite Athletes With Asthma. Unknown status NCT00914901 Phase 4 inhaled salmeterol
26 Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia-single Center,Randomized,Double-blind,Controlled Trial Unknown status NCT02289391 Phase 4 Anesthesia induction;Anesthesia maintenance;Assisted anesthesia
27 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
28 Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids Unknown status NCT00397267 Phase 4 inhalation of corticosteroids
29 Efficacy of Bronchial Thermoplasty in Korean Patients With Severe Asthma Unknown status NCT02031263 Phase 4
30 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
31 A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma. Unknown status NCT01939951 Phase 4
32 Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02053402 Phase 4 Vitamin D
33 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma Unknown status NCT00385359 Phase 4 Albuterol
34 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Unknown status NCT03034005 Phase 4 Budesonide
35 Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS. Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
36 Comparison of Different Methodologies Assessing Airway Responsiveness and Investigation of Treatment Efficacy of Budesonide /Formoterol in Asthmatics Unknown status NCT02574975 Phase 4 methacholine;adenosine monophosphate;leukotriene D4;budesonide /formoterol
37 Extra-fine Formoterol/Beclomethasone in the Treatment of Asthmatic Crisis Unknown status NCT02345993 Phase 4 Extra fine Formoterol/Beclomethasone
38 Efficacy and Safety of Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children: A Double-Blind, Randomized, and Placebo-Controlled Study Unknown status NCT00172341 Phase 4 Staloral TM
39 Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment. Unknown status NCT02002754 Phase 4 Bambuterol Hydrochloride tablets
40 Time-Effect of Montelukast on Protection Against Exercise-Induced Bronchoconstriction Completed NCT00935415 Phase 4 Montelukast;Placebo
41 A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm Completed NCT00118716 Phase 4 Fluticasone propionate/salmeterol;Fluticasone Propionate
42 A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm Completed NCT00118690 Phase 4 Fluticasone propionate/salmeterol
43 Effects on Small Airways Obstruction of Two Long-term Treatments With Extrafine Beclomethasone/Formoterol vs Fluticasone/Salmeterol in Asthma Completed NCT01255579 Phase 4 Salmeterol Fluticasone;formoterol - beclometasone
44 Varenicline and Advanced Behavioral Support on Smoking Cessation and Quality of Life in Inpatients With Acute Exacerbation of COPD, Bronchial Asthma Attack, or Community-acquired Pneumonia: a Prospective Open-label 52-week Follow-up Trial Completed NCT02922387 Phase 4 Varenicline
45 A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma Completed NCT01462344 Phase 4 ADVAIR 100/50mcg;ADVAIR 250/50mcg;FLOVENT 100mcg;FLOVENT 250mcg
46 Clinical Study of the Safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in Children With Asthma of Varying Levels of Severity Completed NCT03600428 Phase 4
47 Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation Completed NCT01403467 Phase 4
48 A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD). Completed NCT00862641 Phase 4 Regadenoson;Placebo
49 A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season. Completed NCT01192178 Phase 4 FLOVENT™ DISKUS™ 100 mcg BID;ADVAIR™ DISKUS™ 100/50 mcg BID
50 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects With Asthma and Exercise-Induced Bronchoconstriction Completed NCT02730351 Phase 4 Fluticasone furoate/ Vilanterol 100 mcg/25 mcg;Fluticasone propionate 250 mcg;Placebo via ELLIPTA inhaler;Placebo via DISKUS / ACCUHALER

Search NIH Clinical Center for Asthma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Albuterol
ALBUTEROL SO4 PWDR
Albuterol Sulfate
Aminophylline
aminophylline dihydrate
AMINOPHYLLINE PWDR
ANTIASTHMA,ANTILEUKOTRIENES
ANTIASTHMA,OTHER
ANTIASTHMA/BRONCHODILATORS
ANTI-INFLAMMATORIES,INHALATION
bitolterol
bitolterol mesylate
BRONCHODILATORS,ANTICHOLINERGIC
BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION
BRONCHODILATORS,SYMPATHOMIMETIC,ORAL
BRONCHODILATORS,XANTHINE-DERIVATIVE
Cromolyn
Cromolyn Sodium
Ephedra vulgaris preparation
Ephedrine
Ephedrine hydrochloride
Ephedrine sulfate
EPHEDRINE TANNATE
formoterol
formoterol fumarate
formoterol fumarate dihydrate
iodinated glycerol
Isoetharine
Isoetharine hydrochloride
Isoetharine Mesylate
metaproterenol
Metaproterenol Sulfate
montelukast
montelukast sodium
oxtriphylline
pirbuterol
Pirbuterol acetate
Pseudoephedrine
Pseudoephedrine Hydrochloride
Pseudoephedrine sulfate
salmeterol
Salmeterol xinafoate
Terbutaline
Terbutaline Sulfate
Theophylline
Theophylline anhydrous
Theophylline calcium salicylate
Theophylline Sodium Glycinate
zafirlukast
zileuton

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Asthma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Asthma:
Bone marrow-derived mesenchymal stem cells for severe refractory asthma
Embryonic/Adult Cultured Cells Related to Asthma:
Mouse bone marrow-derived mesenchymal stem cells (family) PMIDs: 20801416 21653527

Cochrane evidence based reviews: asthma

Genetic Tests for Asthma

Genetic tests related to Asthma:

# Genetic test Affiliating Genes
1 Asthma, Susceptibility to 29 ADRB2 ALOX5 CCL11 HLA-G HNMT IL13 MUC7 PLA2G7 SCGB3A2 TNF
2 Asthma 29

Anatomical Context for Asthma

MalaCards organs/tissues related to Asthma:

40
Smooth Muscle, Lung, T Cells, Heart, Skin, Bone, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Asthma:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Trachea Airway Smooth Muscle Cells Affected by disease, potential therapeutic candidate

Publications for Asthma

Articles related to Asthma:

(show top 50) (show all 33140)
# Title Authors PMID Year
1
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. 54 57 6 61
11709756 2002
2
A hexanucleotide repeat upstream of eotaxin gene promoter is associated with asthma, serum total IgE and plasma eotaxin levels. 54 57 6
17220216 2007
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 54 57 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 54 6 57
14681301 2004
5
A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma. 54 57 6
11813133 2002
6
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 54 6 57
11896460 2002
7
Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. 57 6 54
11588017 2001
8
Genetic variants of IL-13 signalling and human asthma and atopy. 54 57 6
10699178 2000
9
MUC7 haplotype analysis: results from a longitudinal birth cohort support protective effect of the MUC7*5 allele on respiratory function. 57 6
16759176 2006
10
Genetic polymorphism of MUC7: allele frequencies and association with asthma. 6 57
11378823 2001
11
Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. 57 61 54
12913068 2003
12
The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. 54 57
16841093 2006
13
Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. 6 54
16596417 2006
14
A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p. 61 57
16391567 2006
15
A testing framework for identifying susceptibility genes in the presence of epistasis. 57 54
16385446 2006
16
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. 6 54
15867853 2005
17
No association of histamine- N-methyltransferase polymorphism with asthma or bronchial hyperresponsiveness in two German pediatric populations. 54 6
15693910 2005
18
Lack of association of histamine-N-methyltransferase (HNMT) polymorphisms with asthma in the Indian population. 6 54
16205835 2005
19
Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. 57 54
15345705 2004
20
Association of Eotaxin gene family with asthma and serum total IgE. 54 57
12761043 2003
21
Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. 54 57
12110844 2002
22
STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. 54 57
11912176 2002
23
Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study on the genetics of asthma. 57 61
11349227 2001
24
TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. 54 57
11295643 2001
25
Meta-analysis for linkage to asthma and atopy in the chromosome 5q31-33 candidate region. 61 57
21523954 2001
26
Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. 54 57
11093275 2000
27
Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. 57 54
10973279 2000
28
The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. 57 54
10733466 2000
29
Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. 54 6
10803682 2000
30
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. 6 54
10369259 1999
31
A genome-wide search for linkage to asthma. German Asthma Genetics Group. 61 57
10333435 1999
32
Asthma and bronchial hyperresponsiveness linked to the XY long arm pseudoautosomal region. 54 57
9782093 1998
33
Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. 61 57
9700192 1998
34
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. 6 54
9399966 1997
35
Interleukin 9: a candidate gene for asthma. 57 54
9371819 1997
36
Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. 57 54
9372650 1997
37
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. 54 6
9062372 1997
38
Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. 54 6
7706471 1995
39
Association of chronic rhinosinusitis with bronchial asthma and its severity: A protocol for systematic review and meta-analysis. 42 61
33655940 2021
40
A comparison of efficacy and safety of complementary and alternative therapies for children with asthma: A protocol for systematic review and meta analysis. 61 42
33725965 2021
41
Analysis of the relationship between asthma and benign prostatic hyperplasia: A STROBE-compliant study. 42 61
33726017 2021
42
A large-scale, consortium-based genomewide association study of asthma. 57
20860503 2010
43
Variants of DENND1B associated with asthma in children. 57
20032318 2010
44
PRKCA: a positional candidate gene for body mass index and asthma. 57
19576566 2009
45
An african-specific functional polymorphism in KCNMB1 shows sex-specific association with asthma severity. 57
18535015 2008
46
Allele-specific targeting of microRNAs to HLA-G and risk of asthma. 47 54
17847008 2007
47
A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. 57
17589520 2007
48
IRAK-M is involved in the pathogenesis of early-onset persistent asthma. 57
17503328 2007
49
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. 57
17182589 2007
50
Significant linkage to airway responsiveness on chromosome 12q24 in families of children with asthma in Costa Rica. 57
17024367 2007